Super NK cell therapy / Qihan Biotech - LARVOL DELTA

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=102 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33

Off-the-Shelf iPSC-Derived Nature Killer Cells with Enhanced Expression of NK Activating Receptors for the Treatment of Solid Tumors (ASGCT 2022) - "Here we report QN-030 (“Super NK cells”), an investigational, iPSC-derived NK cell product with enhanced expression of a variety of activating receptors (NKG2D and NCRs) intended for the treatment of solid tumors...Close monitoring of NKG2D/NCR expression revealed the potential mechanism of enhanced tumor killing activity. Together, we have engineered iPSC-derived QN-030 NK cells as a promising clinical drug candidate for treatment of solid tumors."

IO biomarker • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor • IL15 • NKG2D

"Super NK cells" - natural killer cells derived from engineered hiPSC with enhanced NK receptor expression demonstrate better anti-tumor effects for solid tumors (AACR 2022) - "More importantly, the “super NK cells” show improved cytotoxicity to multiple solid tumors in both in vitro system and in vivo xenograft mouse models. In summary, we have engineered hiPSCs which can be differentiated into "super NK cells" as a potential cell therapy product for improved efficacy against solid tumors."

IO biomarker • Hematological Malignancies • Oncology • Solid Tumor • NKG2D

Qihan Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2022 (Businesswire) - "Hangzhou Qihan Biotechnology Co., Ltd...announced preclinical data from its NK cell programs, presented during the poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, Louisiana. NK cells derived from genetically engineered human induced pluripotent stem cells (iPSCs) hold great potential to become the next-generation allogeneic cell therapy products."

Preclinical • Oncology